Pfizer licenses Novavax Matrix-M adjuvant for up to 2 vaccine programs

Novavax signed a non-exclusive licensing deal giving Pfizer access to Novavax’s Matrix-M adjuvant for use in vaccines targeting up to 2 infectious disease areas.

Novavax gets a $30M upfront payment in Q1 2026, is eligible for up to $500M in development and sales milestones, and tiered high mid-single-digit royalties on net sales of any Pfizer products that use Matrix-M. Pfizer controls development, manufacturing, and commercialisation, while Novavax supplies Matrix-M.

Why the market cares

1. This is a “platform monetisation” signal: Novavax is getting paid for the ingredient (adjuvant), not just a single vaccine product. That can create higher-quality, longer-duration cash flows (upfront + milestones + royalties).

2. It’s also a sen ...